市場調查報告書

麩質過敏症(CD) - 市場考察,流行病學,市場預測 (2027年)

Celiac Disease (CD) Market Insight, Epidemiology and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 401978
出版日期 內容資訊 英文 150 Pages
商品交期: 最快1-2個工作天內
價格
麩質過敏症(CD) - 市場考察,流行病學,市場預測 (2027年) Celiac Disease (CD) Market Insight, Epidemiology and Market Forecast - 2030
出版日期: 2020年01月01日內容資訊: 英文 150 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的麩質過敏症(CD)的總患病數2016年達402萬7,782人,市場規模2015年價值5,470萬美元。

本報告提供麩質過敏症(CD)市場相關調查,疾病概要,主要7個國家的市場趨勢,罹患數、患病數、市場規模的變化與預測(過去3年、今後10年份),市場成長要素及障礙分析,開發中/已上市的治療藥的簡介,潛在成長性,目前未滿足需求等總括性彙整。

目錄

第1章 報告概要

第2章 麩質過敏症市場概要

第3章 疾病背景和概要

  • 簡介
  • 麩質過敏症的種類
  • 原因
  • 症狀
  • 發病機制
    • 難治性麩質過敏症(RCD)I型
    • 難治性麩質過敏症(RCD)II型
  • 診斷
    • 美國胃腸病學會(ACG):推薦指南
    • 英國胃腸病學會:成人麩質過敏症的診斷指南

第4章 流行病學和患者人口

  • 主要的觀察
  • 人口與預測參數
  • 美國
    • 麩質過敏症的患病數
    • 麩質過敏症的罹患數
    • 治療可能的病例數
  • 德國
    • 麩質過敏症的患病數
    • 麩質過敏症的罹患數
    • 治療可能的病例數
  • 法國
    • 麩質過敏症的患病數
    • 麩質過敏症的罹患數
    • 治療可能的病例數
  • 西班牙
    • 麩質過敏症的患病數
    • 麩質過敏症的罹患數
    • 治療可能的病例數
  • 義大利
    • 麩質過敏症的患病數
    • 麩質過敏症的罹患數
    • 治療可能的病例數
  • 英國
    • 麩質過敏症的患病數
    • 麩質過敏症的罹患數
    • 治療可能的病例數
  • 日本
    • 麩質過敏症的患病數
    • 麩質過敏症的罹患數
    • 可治療的病例數

第5章 麩質過敏症的治療

  • 無反應、難治性麩質過敏症的治療方法
  • 麩質過敏症的治療領域
  • 美國胃腸病學會(ACG):推薦指南
  • 英國胃腸病學會:成人麩質過敏症的診斷指南

第6章 未滿足需求

第7章 開發中的治療藥

  • Larazotide Acetate:Innovate Biopharmaceuticals
    • 法規的里程碑
    • 開發活動
    • 臨床開發
    • 進行中的臨床試驗資訊
    • 安全性和有效性
    • 優點與缺點
    • 產品的簡介
  • Latiglutenase (ALV003):ImmunogenX
  • AMG 714:Celimmune
  • Nexvax2:Immusant Inc.
  • BL-7010:BioLineRx Ltd
  • Vedolizumab:武田藥品

第8章 麩質過敏症的市場分析

  • 主要的觀察
  • 全球麩質過敏症市場
  • 主要7個國家的麩質過敏症市場
  • 美國
    • 市場規模
    • 市場規模:各治療藥物
  • 歐盟5國
    • 市場規模
    • 市場規模:各治療藥物
      • 義大利
      • 德國
      • 法國
      • 英國
      • 西班牙
    • 日本
  • 市場規模
  • 市場規模:各治療藥物

第9章 市場成長要素

第10章 市場障礙

第11章 附錄

第12章 調查手法

第13章 諮詢服務

第14章 免責聲明

第15章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0012

DelveInsight's "Celiac Disease (CD) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Celiac Disease (CD), historical and forecasted epidemiology as well as the Celiac Disease (CD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Celiac Disease (CD) market report provides current treatment practices, emerging drugs, Celiac Disease (CD) market share of the individual therapies, current and forecasted Celiac Disease (CD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Celiac Disease (CD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Celiac Disease (CD) Disease Understanding and Treatment Algorithm

The DelveInsight Celiac Disease (CD) market report gives a thorough understanding of the Celiac Disease (CD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Celiac Disease (CD).

Treatment

It covers the details of conventional and current medical therapies available in the Celiac Disease (CD) market for the treatment of the condition. It also provides Celiac Disease (CD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Celiac Disease (CD) Epidemiology

The Celiac Disease (CD) epidemiology division provide insights about historical and current Celiac Disease (CD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Celiac Disease (CD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Celiac Disease (CD) Epidemiology

The epidemiology segment also provides the Celiac Disease (CD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Celiac Disease (CD) Drug Chapters

Drug chapter segment of the Celiac Disease (CD) report encloses the detailed analysis of Celiac Disease (CD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Celiac Disease (CD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Celiac Disease (CD) treatment.

Celiac Disease (CD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Celiac Disease (CD) treatment.

Celiac Disease (CD) Market Outlook

The Celiac Disease (CD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Celiac Disease (CD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Celiac Disease (CD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Celiac Disease (CD) market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Celiac Disease (CD) market in 7MM.

The United States Market Outlook

This section provides the total Celiac Disease (CD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Celiac Disease (CD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Celiac Disease (CD) market size and market size by therapies in Japan is also mentioned.

Celiac Disease (CD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Celiac Disease (CD) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Celiac Disease (CD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Celiac Disease (CD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Celiac Disease (CD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Celiac Disease (CD) emerging therapies.

Reimbursement Scenario in Celiac Disease (CD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Celiac Disease (CD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Celiac Disease (CD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Celiac Disease (CD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Celiac Disease (CD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Celiac Disease (CD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Celiac Disease (CD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Celiac Disease (CD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Celiac Disease (CD) market

Report Highlights

  • In the coming years, Celiac Disease (CD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Celiac Disease (CD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Celiac Disease (CD). Launch of emerging therapies will significantly impact the Celiac Disease (CD) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Celiac Disease (CD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Celiac Disease (CD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Celiac Disease (CD) Pipeline Analysis
  • Celiac Disease (CD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Celiac Disease (CD) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage

Celiac Disease (CD) Epidemiology Segmentation

  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Celiac Disease (CD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Celiac Disease (CD) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Celiac Disease (CD) total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Celiac Disease (CD) market size during the forecast period (2017-2030)?
  • At what CAGR, the Celiac Disease (CD) market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Celiac Disease (CD) market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Celiac Disease (CD) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Celiac Disease (CD)?
  • What is the historical Celiac Disease (CD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Celiac Disease (CD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Celiac Disease (CD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Celiac Disease (CD) during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?
  • Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
  • What are the current options for the Celiac Disease (CD) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Celiac Disease (CD) in the USA, Europe, and Japan?
  • What are the Celiac Disease (CD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Celiac Disease (CD)?
  • How many therapies are developed by each company for Celiac Disease (CD) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Celiac Disease (CD) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Celiac Disease (CD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Celiac Disease (CD) and their status?
  • What are the key designations that have been granted for the emerging therapies for Celiac Disease (CD)?
  • What are the global historical and forecasted market of Celiac Disease (CD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Celiac Disease (CD) market
  • To understand the future market competition in the Celiac Disease (CD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Celiac Disease (CD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Celiac Disease (CD) market
  • To understand the future market competition in the Celiac Disease (CD) market

Table of Contents

1. Key Insights

2. Executive Summary of Celiac Disease (CD)

3. Competitive Intelligence Analysis for Celiac Disease (CD)

4. Celiac Disease (CD): Market Overview at a Glance

  • 4.1. Celiac Disease (CD) Total Market Share (%) Distribution in 2017
  • 4.2. Celiac Disease (CD) Total Market Share (%) Distribution in 2030

5. Celiac Disease (CD): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Sign and Symptoms
  • 5.3. Pathophysiology
  • 5.4. Risk Factors
  • 5.5. Diagnosis

6. Patient Journey

7. Celiac Disease (CD) Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale: 7MM
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Celiac Disease (CD) Epidemiology Scenario in the 7MM (2017-2030)
  • 7.4. United States Epidemiology
    • 7.4.1. Celiac Disease (CD) Epidemiology Scenario in the United States (2017-2030)
  • 7.5. EU-5 Country-wise Epidemiology
    • 7.5.1. Germany Epidemiology
      • 7.5.1.1. Celiac Disease (CD) Epidemiology Scenario in Germany (2017-2030)
    • 7.5.2. France Epidemiology
      • 7.5.2.1. Celiac Disease (CD) Epidemiology Scenario in France (2017-2030)
    • 7.5.3. Italy Epidemiology
      • 7.5.3.1. Celiac Disease (CD) Epidemiology Scenario in Italy (2017-2030)
    • 7.5.4. Spain Epidemiology
      • 7.5.4.1. Celiac Disease (CD) Epidemiology Scenario in Spain (2017-2030)
    • 7.5.5. United Kingdom Epidemiology
      • 7.5.5.1. Celiac Disease (CD) Epidemiology Scenario in the United Kingdom (2017-2030)
    • 7.5.6. Japan Epidemiology
      • 7.5.6.1. Celiac Disease (CD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1. Celiac Disease (CD) Treatment and Management
  • 8.2. Celiac Disease (CD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Celiac Disease (CD) Treatment

11. Marketed Products

  • 11.1. List of Marketed Products in the 7MM
  • 11.2. Drug Name: Company Name
    • 11.2.1. Product Description
    • 11.2.2. Regulatory Milestones
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Pivotal Clinical Trials
    • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

  • 12.1. Key Cross
  • 12.2. Drug Name: Company Name
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile

List to be continued in report

13. Celiac Disease (CD): Seven Major Market Analysis

  • 13.1. Key Findings
  • 13.2. Celiac Disease (CD) Market Size in 7MM
  • 13.3. Celiac Disease (CD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

  • 15.1. United States: Market Size
    • 15.1.1. Celiac Disease (CD) Total Market Size in the United States
    • 15.1.2. Celiac Disease (CD) Market Size by Therapies in the United States
  • 15.2. EU-5 countries: Market Size and Outlook
  • 15.3. Germany Market Size
    • 15.3.1. Celiac Disease (CD) Total Market Size in Germany
    • 15.3.2. Celiac Disease (CD) Market Size by Therapies in Germany
  • 15.4. France Market Size
    • 15.4.1. Celiac Disease (CD) Total Market Size in France
    • 15.4.2. Celiac Disease (CD) Market Size by Therapies in France
  • 15.5. Italy Market Size
    • 15.5.1. Celiac Disease (CD) Total Market Size in Italy
    • 15.5.2. Celiac Disease (CD) Market Size by Therapies in Italy
  • 15.6. Spain Market Size
    • 15.6.1. Celiac Disease (CD) Total Market Size in Spain
    • 15.6.2. Celiac Disease (CD) Market Size by Therapies in Spain
  • 15.7. United Kingdom Market Size
    • 15.7.1. Celiac Disease (CD) Total Market Size in the United Kingdom
    • 15.7.2. Celiac Disease (CD) Market Size by Therapies in the United Kingdom
  • 15.8. Japan Market Outlook
    • 15.8.1. Japan Market Size
    • 15.8.2. Celiac Disease (CD) Total Market Size in Japan
    • 15.8.3. Celiac Disease (CD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Celiac Disease (CD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

  • 20.1. Bibliography
  • 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1 : 7MM Celiac Disease (CD) Epidemiology (2017-2030)
  • Table 2 : 7MM Celiac Disease (CD) Diagnosed and Treatable Cases (2017-2030)
  • Table 3 : Disease% Epidemiology in the United States (2017-2030)
  • Table 4 : Celiac Disease (CD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5 : Celiac Disease (CD) Epidemiology in Germany (2017-2030)
  • Table 6 : Celiac Disease (CD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7 : Celiac Disease (CD) Epidemiology in France (2017-2030)
  • Table 8 : Celiac Disease (CD) Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9 : Celiac Disease (CD) Epidemiology in Italy (2017-2030)
  • Table 10 : Celiac Disease (CD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11 : Celiac Disease (CD) Epidemiology in Spain (2017-2030)
  • Table 12 : Celiac Disease (CD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13 : Celiac Disease (CD) Epidemiology in the UK (2017-2030)
  • Table 14 : Celiac Disease (CD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Table 15 : Celiac Disease (CD) Epidemiology in Japan (2017-2030)
  • Table 16 : Celiac Disease (CD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Table 17 : Drug Name, Clinical Trials by Recruitment status
  • Table 18 : Drug Name, Clinical Trials by Zone
  • Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Table 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Table 22 : United States Market Size in USD, Million (2017-2030)
  • Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Table 24 : Germany Market Size in USD, Million (2017-2030)
  • Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Table 26 : France Market Size in USD, Million (2017-2030)
  • Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Table 28 : Italy Market Size in USD, Million (2017-2030)
  • Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Table 30 : Spain Market Size in USD, Million (2017-2030)
  • Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Table 34 : Japan Market Size in USD, Million (2017-2030)
  • Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)

List of Figures

  • Figure 1 : 7MM Celiac Disease (CD) Epidemiology (2017-2030)
  • Figure 2 : 7MM Celiac Disease (CD) Diagnosed and Treatable Cases (2017-2030)
  • Figure 3 : Celiac Disease (CD) Epidemiology in the United States (2017-2030)
  • Figure 4 : Celiac Disease (CD) Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5 : Celiac Disease (CD) Epidemiology in Germany (2017-2030)
  • Figure 6 : Celiac Disease (CD) Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7 : Celiac Disease (CD) Epidemiology in France (2017-2030)
  • Figure 8 : Celiac Disease (CD) Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9 : Celiac Disease (CD) Epidemiology in Italy (2017-2030)
  • Figure 10 : Celiac Disease (CD) Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11 : Celiac Disease (CD) Epidemiology in Spain (2017-2030)
  • Figure 12 : Celiac Disease (CD) Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13 : Celiac Disease (CD) Epidemiology in the UK (2017-2030)
  • Figure 14 : Celiac Disease (CD) Diagnosed and Treatable Cases in the UK (2017-2030)
  • Figure 15 : Celiac Disease (CD) Epidemiology in Japan (2017-2030)
  • Figure 16 : Celiac Disease (CD) Diagnosed and Treatable Cases in Japan (2017-2030)
  • Figure 17 : Drug Name, Clinical Trials by Recruitment status
  • Figure 18 : Drug Name, Clinical Trials by Zone
  • Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
  • Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
  • Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
  • Figure 22 : United States Market Size in USD, Million (2017-2030)
  • Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
  • Figure 24 : Germany Market Size in USD, Million (2017-2030)
  • Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
  • Figure 26 : France Market Size in USD, Million (2017-2030)
  • Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
  • Figure 28 : Italy Market Size in USD, Million (2017-2030)
  • Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
  • Figure 30 : Spain Market Size in USD, Million (2017-2030)
  • Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
  • Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
  • Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
  • Figure 34 : Japan Market Size in USD, Million (2017-2030)
  • Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)